System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ugo De Giorgi, MD, PhD is an expert in Oncology at Ospedale Vito Fazzi (Italy). As of October 2026, ScienceLeadR ranks Ugo De Giorgi in the top 1% of experts worldwide for Urogenital Neoplasms, Prostatic Diseases and Kidney Neoplasms. Ugo De Giorgi has authored 849 publications, the most recent in 2026, and is an investigator in 77 clinical trials, 10 of them ongoing. SLR score: 4,093 (community average: 125). How the SLR is computed.

LeadR Profile

Ugo De Giorgi, MD, PhD Ospedale Vito Fazzi Italy
4 093 ScienceLeadR Reputation 4093

Unlock

Register Login
Network Map

Oncology

Subspecialties: Urology - Biochemistry - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1997 - 2026
Source: PubMed

University of Salento

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 849

Citations

Citations: 49 004 1st author: 71 Last author: 155 Unique author: 3

Main journals

J Clin Oncol 180
Ann Oncol 53
N Engl J Med 30
Clin Genitourin Cancer 25
Front Oncol 23

Best Journals

J Clin Oncol 107
N Engl J Med 29
Ann Oncol 22

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study.
PMID 42886889 — neoplasms, precision medicine, therapeutics, mutation, endometrial neoplasms, msi-h		JCO Precis Oncol20260
Real-World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON-3 Study.
PMID 42862920 — research design, genes, genomics, poly(adp-ribose) polymerases, neoplasms, prostate, poly adenosine diphosphate ribose, biomarkers, recombinational dna repair, prostatic neoplasms, precision medicine		Prostate20260
The RNA cargo of plasma-derived extracellular vesicles in mCRPC patients captures cancer cells and tumor microenvironment signals.
PMID 42818596 — cells, extracellular vesicles, neoplasms, disease progression, prostate, prostatic neoplasms, tissues, tumor microenvironment, plasma		bioRxiv20260
Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy.
PMID 42722919 — serum, carcinoembryonic antigen, neoplasms, prostate, biomarkers, prostatic neoplasms, nuclear medicine, castration, therapeutics		Eur J Nucl Med Mol Imaging20260
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
PMID 42685569 — breast neoplasms, neoplasms, breast, therapeutics		Eur J Cancer20261

Clinical Studies 77

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Study Chair: 1

By phase:

Phase 3 47
Phase 2 20
N/A 8
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 42
Active not recruiting 21
Recruiting 9
Terminated 4
Unknown 1

By type:

Interventional 70
Observational 7

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 2
multicentric5to9 1
multicentricup10 67

Main Topics

Cohort/Consortium Investigators 5

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase II trial of atezolizumab plus CArboplatin plus nab Paclitaxel as first line Therapy in metastatic triple negative PD L1 positive breast cancer patients
2024-519514-31-00 — breast neoplasms, paclitaxel, neoplasms, breast, therapeutics, carboplatin		Phase 2Recruiting2025
A Three Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum Resistant (Part A) and Platinum Sensitive (Parts B and C) Ovarian Cancer
NCT07213804 — paclitaxel, pharmaceutical preparations, fallopian tube neoplasms, ovary, doxorubicin, neoplasms, bevacizumab, drug therapy, maytansine, neoplasm metastasis, ovarian neoplasms, peritoneal neoplasms, therapeutics, topotecan, carboplatin, folate receptor 1, fallopian tubes, chemotherapy		Phase 3Recruiting2025
MITO 25 1 A randomized molecular driven phase II trial of Carboplatin Paclitaxel Bevacizumab vs Carboplatin Paclitaxel Bevacizumab Rucaparib vs Carboplatin Paclitaxel Rucaparib selected according to HRD status in patients with advanced (stage III B C IV) ovarian primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib Bevacizumab combination
2024-516632-99-00 — paclitaxel, fallopian tube neoplasms, ovary, neoplasms, bevacizumab, carboplatin, fallopian tubes		Phase 2Active not recruiting2021
Prospective and Multicenter Italian Registry of Locally Advanced Metastatic Urothelial Carcinoma
NCT06235268 — registries, carcinoma, transitional cell, cells, therapeutics, palliative care, carcinoma		N/ARecruiting2023
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild Type Advanced or Recurrent Endometrial Carcinoma
NCT05611931 — administration, oral, neoplasms, dosage forms, tablets, maintenance, response evaluation criteria in solid tumors, therapeutics, endometrial neoplasms, carcinoma		Phase 3Active not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS